- Home
- COMP vs PRAX Comparison
COMP vs PRAX Comparison
Compare COMP & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COMP | PRAX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.0B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | COMP | PRAX |
|---|---|---|
| Price | $10.67 | $295.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $10.83 | ★ $373.79 |
| AVG Volume (30 Days) | ★ 9.7M | 840.2K |
| Earning Date | 02-17-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,642,200,000.00 | $7,463,000.00 |
| Revenue This Year | $25.14 | N/A |
| Revenue Next Year | $12.29 | $12,467.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.27 | ★ 364.98 |
| 52 Week Low | $5.10 | $26.70 |
| 52 Week High | $11.07 | $317.72 |
Technical Indicators
Market Signals| Indicator | COMP | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 67.94 |
| Support Level | $10.44 | $266.51 |
| Resistance Level | $10.79 | $317.72 |
| Average True Range (ATR) | 0.36 | 13.72 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 53.48 | 64.45 |
Price Performance
Historical ComparisonAbout COMP Compass Inc.
Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.